AMH and Functional Hypothalamic Amenorrhea

Last updated: June 16, 2023
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Amenorrhea

Treatment

venous sampling

Clinical Study ID

NCT05921877
5321
  • Ages 15-34
  • Female

Study Summary

The purpose of this study is to analyze AMH levels in patients with prolonged FHA (more than 2 years). Based on previous studies, we can assume that prolonged FHA may mimic a condition of primary hypogonadotropic hypogonadism, due to a lasting interruption of gonadotropin release. Furthermore, after the resumption of the spontaneous menstrual cycle, we will reanalyze AMH levels, which we hypothesize to find higher. If our hypotheses are confirmed correct, we could support the thesis that AMH is not a good index of ovarian reserve in patients with functional hypothalamic amenorrhea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women aged 15-34 years.
  • Diagnosis of functional hypothalamic amenorrhea (for at least 2 years).
  • Signature of informed consent.

Exclusion

Exclusion Criteria:

  • Polycystic ovary syndrome
  • Taking oral contraceptives in the previous three months
  • Other clinically relevant endocrinopathies
  • positive MAP-test (Medroxyprogesterone acetate test)
  • Estroprogestin replacement therapy
  • Autoimmune disorders
  • Failure to sign informed consent

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: venous sampling
Phase:
Study Start date:
June 16, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Rosanna Apa

    Rome, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.